XKRX
060280
Market cap264mUSD
Oct 08, Last price
8,620.00KRW
1D
-0.69%
1Q
-1.03%
Jan 2017
66.73%
IPO
144.89%
Name
Curexo Inc
Chart & performance
P/E
127.74
P/S
4.77
EPS
67.48
Div yield, %
—
Shrs. gr., 5y
4.25%
Rev. gr., 5y
13.67%
Revenues
74.54b
+34.24%
Net income
2.78b
P
CFO
-11.26b
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CUREXO, Inc. specializes in the creation and distribution of medical technology. The company's activities are organized across three primary divisions: Medical Robot, Implant, and Trade. Its Medical Robot segment focuses on advanced robotic systems designed for surgical procedures, such as joint replacement and spinal operations, in addition to rehabilitation robots and other specialized medical devices. The Implant division is dedicated to manufacturing artificial joint prostheses and a range of other internal body implants. A unique aspect of the company is its Trade division, which manages the import and sale of food products. CUREXO was established on February 29, 1992, and its main offices are situated in Seoul, South Korea.
Key people
Hun Sang Cho
Vice President
Jae Jun Lee
Chief Executive Officer, Vice President, Director · since 2012
Jin Seok Seo
Vice President · since 2011
Yeong Min Jung
Internal Auditor · since 2011
Bong Chu Kim
Assistant Managing Director
Ki Mun In
Director · since 2012
Yong Chan Jung
Managing Director · since 2014
Jeong Ha Kim
Director
Seong Myeon Kim
Director
Director · since 2022
Tae Gyu Park
Director · since 2011
Non-Executive Independent Director · since 2006
Gi Wuk Gyung
Non-Executive Independent Director
Jun Hui Jung
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2022
Gyeong Oh Noh
Non-Executive Independent Director · since 2024
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||